CMPS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

10.210

Open

8.645

VWAP

9.43

Vol

39.75M

Mkt Cap

1.28B

Low

8.630

Amount

374.99M

EV/EBITDA(TTM)

--

Total Shares

134.92M

EV

1.16B

EV/OCF(TTM)

--

P/S(TTM)

--

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Show More

Events Timeline

(ET)

2026-04-20

16:30:00

Major Averages Decline Amid Escalating Tensions with Iran

2026-04-20

12:00:00

Major Averages Decline Amid Rising Tensions with Iran

2026-04-19 (ET)

2026-04-19

13:10:00

Compass Pathways Welcomes White House Executive Order on Accelerating Treatments for Mental Illness

2026-04-17 (ET)

2026-04-17

10:00:00

Trump Administration to Examine Ibogaine Drug Safety

2026-04-16 (ET)

2026-04-16

12:10:00

White House Considers Safety Review of Ibogaine

2026-04-16

11:30:00

Clearmind's CMND-100 Meets Primary Safety Endpoint

2026-03-26 (ET)

2026-03-26

11:00:00

Compass Pathways Q4 Earnings Show Cash Sufficient Until 2028

News

Fool

PinnedWhite House Executive Order Boosts Compass Pathways Stock Surge

stocktwits

04:10 AMstocktwits

BlackBerry and Nvidia Deepen Partnership for AI Safety Systems

CNBC

Trump Signs Executive Order to Accelerate Psychedelic Research

Newsfilter

04-20Newsfilter

White House Psychedelics Executive Order Accelerates Research

stocktwits

04-20stocktwits

AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News

CNBC

Midday Market Moves: Notable Stock Fluctuations

7 Analyst Rating

Wall Street analysts forecast CMPS stock price to rise

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

18.43

High

40.00

Current: 0.000

Low

8.00

Averages

18.43

High

40.00

Canaccord

Buy

to

Buy

downgrade

$20 -> $18

AI Analysis

2026-03-25

Reason

Canaccord

Price Target

$20 -> $18

AI Analysis

2026-03-25

downgrade

Buy

to

Buy

Reason

Canaccord lowered the firm's price target on Compass Pathways to $18 from $20 and keeps a Buy rating on the shares.

Stifel

Buy

maintain

$11 -> $14

2026-03-25

Reason

Stifel

Price Target

$11 -> $14

2026-03-25

maintain

Buy

Reason

Stifel raised the firm's price target on Compass Pathways to $14 from $11 and keeps a Buy rating on the shares. The firm reiterated its Buy view following Q4 earnings, where completion of the rolling NDA is on track for 4Q26. With recent positive topline from Part-A of the '006 Phase 3 study, plus encouraging 26-week durability from Part B of the '005 study, Compass plans to meet with the FDA to confirm alignment on the rolling submission and the path to approval, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMPS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Compass Pathways PLC (CMPS.O) is 0.00, compared to its 5-year average forward P/E of -5.89. For a more detailed relative valuation and DCF analysis to assess Compass Pathways PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.89

Current PE

0.00

Overvalued PE

-0.38

Undervalued PE

-11.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.85

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.24

Undervalued EV/EBITDA

-8.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

90.36

Current PS

24.99

Overvalued PS

487.74

Undervalued PS

-307.01

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Day trading stocks

Intellectia · 26 candidates

Region: USPrice: $5.00 - $80.00Price Change Pct: >= $5.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

GlobalFoundries Inc

32.26B

United Microelectronics Corp

31.75B

Sirius XM Holdings Inc

9.16B

Hims & Hers Health Inc

7.07B

Legend Biotech Corp

4.64B

BlackBerry Ltd

3.23B

what stocks have have hit pivot bottom

Intellectia · 247 candidates

Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000

Ticker

Name

Market Cap$

Lifecore Biomedical Inc

149.91M

NovaGold Resources Inc

3.54B

GoldMining Inc

243.68M

Clearpoint Neuro Inc

282.10M

Paramount Gold Nevada Corp

137.45M

Can Fite Biopharma Ltd

6.59M

Whales Holding CMPS

GMT Capital Corp.

RTW Investments, LP

Deep Track Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Compass Pathways PLC (CMPS) stock price today?

The current price of CMPS is 9.46 USD — it has increased 42.04

What is Compass Pathways PLC (CMPS)'s business?

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

What is the price predicton of CMPS Stock?

Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is18.43 USD with a low forecast of 8.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Compass Pathways PLC (CMPS)'s revenue for the last quarter?

Compass Pathways PLC revenue for the last quarter amounts to -45.95M USD, decreased -5.09

What is Compass Pathways PLC (CMPS)'s earnings per share (EPS) for the last quarter?

Compass Pathways PLC. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Compass Pathways PLC (CMPS). have?

Compass Pathways PLC (CMPS) has 156 emplpoyees as of April 21 2026.

What is Compass Pathways PLC (CMPS) market cap?

Today CMPS has the market capitalization of 1.28B USD.